BRAF mutations are detectable in about 5-15% of metastatic colorectal cancer (mCRC) patients and represent a clear negative prognostic factor. While in BRAF-mutated (BRAFmt) metastatic melanoma TKI target therapies (BRAF and MEK inhibitor), both alone or in combination, have shown significant efficacy, in BRAFmt CRC single-agent BRAF-inhibitors as well as chemotherapy seem to be ineffective. The critical role of EGFR in CRC and its multiple downstreaming pathways seem to be involved in this lack of response. In recent years, preclinical investigations and retrospective studies slowly increased our knowledge on BRAFmt CRC. This review analyses preclinical data and discusses several clinical trials in order to explore new therapeutic strategies targeting BRAFmt mCRC.

BRAF in metastatic colorectal cancer : the future starts now / A. Orlandi, M.A. Calegari, A. Inno, R. Berenato, M. Caporale, M. Niger, I. Bossi, M.D. Bartolomeo, F. De Braud, F. Pietrantonio. - In: PHARMACOGENOMICS. - ISSN 1462-2416. - 16:18(2015 Dec), pp. 2069-2081. [10.2217/pgs.15.140]

BRAF in metastatic colorectal cancer : the future starts now

M. Niger;I. Bossi;F. De Braud;F. Pietrantonio
Ultimo
2015

Abstract

BRAF mutations are detectable in about 5-15% of metastatic colorectal cancer (mCRC) patients and represent a clear negative prognostic factor. While in BRAF-mutated (BRAFmt) metastatic melanoma TKI target therapies (BRAF and MEK inhibitor), both alone or in combination, have shown significant efficacy, in BRAFmt CRC single-agent BRAF-inhibitors as well as chemotherapy seem to be ineffective. The critical role of EGFR in CRC and its multiple downstreaming pathways seem to be involved in this lack of response. In recent years, preclinical investigations and retrospective studies slowly increased our knowledge on BRAFmt CRC. This review analyses preclinical data and discusses several clinical trials in order to explore new therapeutic strategies targeting BRAFmt mCRC.
BRAF; colorectal cancer; immunotherapy; target therapy; Pharmacology; Genetics; Molecular Medicine
Settore MED/06 - Oncologia Medica
dic-2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
pgs.15.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.93 MB
Formato Adobe PDF
1.93 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/425218
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact